ClinicalTrials.gg
CompletedNCT00355082Updated Jan 2, 2017Results posted

Conversion To Monotherapy With Lamictal Extended Release Tablets For Treatment Of Partial Epilepsy

A Phase 3 interventional study of lamotrigine, 300 mg/day and lamotrigine, 250 mg/day in Epilepsy, Partial, sponsored by GlaxoSmithKline. Completed at 103 sites in 8 countries. Open to participants aged 13 Years and older. Per ClinicalTrials.gov, last updated 2017-01-02.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
226
Allocation
Randomized
Ages
13 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 102 studies in Epilepsies, Partial with a site in United States — 18 open to participants now, 24 under way, 6 of them phase 3. Epilepsies, Partial · United States.

Enrollment
26th of 86
226 · median 100
Started
2006
with 3 others
Phase 3
31 of 102
3 open now
Registered
25th of 102
by date

Among the 102 studies in Epilepsies, Partial with a site in United States, this one is the 26th largest by enrollment of the 86 interventional ones that give a count, is one of 4 that started in 2006, is one of 31 in phase 3, and was the 25th registered.

Epilepsies, Partial

243 studies on the registry are indexed under Epilepsies, Partial; 49 are open to participants now.

Browse Epilepsies, Partial studies →

Open to participants now

18 of the 102 studies in Epilepsies, Partial with a site in United States are open now. Recruiting first, the newest first:

13 more — sign in →

All 18 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 37 Epilepsies, Partial studies recruiting now, 9 (24%) set no upper age limit and 24 (65%) stop at 75 or younger; 17 take children under 18; 3 take healthy volunteers.

This study: 13 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 102 studies in Epilepsies, Partial with a site in United States, or all of them as a file.
02

Study summary

This study is being conducted to determine the effectiveness of a lower monotherapy dose of lamotrigine than that currently approved.

Read the detailed description

The study consists of a Treatment phase, where efficacy is determined and a Continuation phase for extended safety information. The Continuation phase is open to all Treatment phase participants and those who did not qualify for treatment because of an insufficient number of seizures during the Baseline phase.

03

Conditions studied

  • Epilepsy, Partial

Keywords

  • epilepsy
  • lamotrigine
  • Lamictal
  • monotherapy
04

Who can participate

Ages eligible
13 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or Female ≥13 years of age
  • Have a confident diagnosis of epilepsy with partial seizures for at least 24 weeks prior to the Baseline Phase
  • Have a documented history of partial seizures such that the investigator must judge that the subject is likely to have at least 4 partial seizures during the 8-week Baseline Phase.
  • Have experienced at least 4 partial seizures (i.e., simple or complex partial seizures with or without secondary generalization) during an 8-week (i.e., 56 days) prospective Baseline Phase with at least one partial seizure occurring during each 4-week (i.e., 28-day) period.
  • NOTE: With prior authorization from GlaxoSmithKline (GSK), retrospective data may take the place of up to the first 4 weeks (i.e., first 28 days) of the Baseline Phase for subjects providing reliable documentation of the following:

    1. A complete daily seizure diary that includes the number, and type (i.e., simple or complex partial seizures with or without secondary generalization), of seizures experienced each day for up to 28 consecutive days immediately prior to the prospective Baseline Phase
    2. Stability of prescribed dosages of background antiepileptic drug (AED)
    3. Compliance with background AED

All subjects permitted to use retrospective baseline data must complete a minimum of four weeks (i.e., 28 days) of the prospective Baseline Phase. The retrospective plus the prospective Baseline Phases must equal the 56 consecutive days prior to the start of dosing with study drug.

  • be currently receiving AED monotherapy treatment with a stable regimen of a non-enzyme inducing AED for at least four weeks prior to starting the Baseline Phase.
  • be able and willing to maintain an accurate, complete, written daily seizure diary, or has a parent/caregiver who is able and willing to maintain and accurate, complete, written daily seizure diary for the entire duration of the study.
  • be able to comply with the dosing of study drugs, background AED, and all study procedures.
  • understand and sign written , or will have a parent or a legally authorized representative who has done so, prior to the performance of any study assessments
  • if female, and of be using an acceptable form of , to include one of the following:

    1. Complete abstinence from intercourse for two weeks before exposure to the study drug, throughout the clinical trial, and for a period after the trial to account for elimination of the drug (a minimum of 2 weeks).
    2. Consistent and correct use of one of the following methods of birth control:

Male partner who is sterile prior to the female subject's entry into the study and is the sole sexual partner for that female subject.

Any intrauterine device (IUD) with a documented failure rate of less than 1% per year

Double barrier method consisting of spermicide plus a mechanical barrier (e.g., spermicide plus a male condom or a female diaphragm).

NOTE: Women who have had a hysterectomy, tubal ligation, or are are considered to be of non-childbearing potential.

NOTE: A pharmacokinetic interaction has been observed between lamotrigine (LTG) and estrogen-based oral contraceptives. Therefore, the use of hormonal therapy (e.g., for contraception or hormone replacement therapy) is not allowed.

Exclusion criteria

Exclusion criteria:

  • Exhibits any primary generalized seizures (e.g., absence, myoclonic primary generalized tonic-clonic seizures).
  • Has had status epilepticus within the 24 weeks prior to, or during, the Baseline Phase.
  • Is taking an enzyme-inducing AED (EIAED - e.g. carbamazepine, phenytoin, phenobarbital, primidone) or is taking more than 1 background AED.
  • Is currently taking lamotrigine (LTG) or has previously had an adequate trial of LTG.
  • Is currently taking felbamate
  • Is using hormone therapy
  • Is abusing alcohol and/or other substances
  • Has taken an drug within the previous 30 days or plans to take an investigational drug anytime during the study.
  • Is receiving chronic treatment with any medication that could influence seizure control
  • NOTE: Use of benzodiazepines is allowed as specified in Section 8.1.2
  • Is currently following the ketogenic diet.
  • Is using vagal nerve stimulation
  • Is planning surgery to control seizures during the study.
  • Is pregnant, breastfeeding, or planning to become pregnant during the study or within the three weeks after the last dose of study drug.
  • Is suffering from acute or progressive neurological disease, severe psychiatric disease or severe mental abnormality that is likely to interfere with the objectives of the study.
  • Has any cardiac, renal, hepatic condition, or a condition that affects the absorption, distribution, metabolism or excretion of drugs.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
226 participants (actual)

Study arms

  • Experimental
    lamotrigine 300

    300 mg/day treatment

    Drug: lamotrigine, 300 mg/day

  • Experimental
    lamotrigine 250

    250 mg/day treatment

    Drug: lamotrigine, 250 mg/day

Interventions

  • Druglamotrigine, 300 mg/day

    Drug page: Lamotrigine

    300 mg/day

    Also known as: lamotrigine

  • Druglamotrigine, 250 mg/day

    Drug page: Lamotrigine

    250 mg/day

06

What researchers measure

Primary outcomes

  1. The Percentage of Participants in the 300 mg/Day Dose Group Who Prematurely Discontinued the Study Between Study Visit 5 (Approximately Week 7) and Visit 9 (End of the Treatment Phase)

    The percentage of participants prematurely discontinuing the study was calculated as the number of participants who discontinued the study divided by the number who reached Visit 5 minus major protocol violators. The Control group is composed of data from other similar studies and is not part of this study.

    Time frame: From Study Visit 5 through Visit 9 of the Treatment Phase (approximately Week 7 through Week 23)

Secondary outcomes

  1. The Percentage of Participants in the 250 mg/Day Dose Group Who Prematurely Discontinued the Study Between Study Visit 5 (Approximately Week 7) and Visit 9 (End of the Treatment Phase)

    The percentage of participants prematurely discontinuing the study was calculated as the number of participants who discontinued the study divided by the number who had reached Visit 5 minus major protocol violators. The Control group was composed of data from other similar studies and is not part of this study.

    Time frame: From Study Visit 5 through Visit 9 of the Treatment phase (approximately Week 7 through Week 23)

  2. Time to Discontinuation in the Treatment Phase

    Time (days) until the participant discontinued the study

    Time frame: From Study Visit 5 through Visit 9 of the Treatment phase (approximately Week 7 through Week 23)

  3. Percentage of Participants Meeting Escape Criteria in the Treatment Phase

    The percentage of participants meeting Escape Criteria was calculated as the number of participants who met an Escape Criterion divided by the number who had reached Visit 5 minus major protocol violators. Escape Criteria are: (1) doubling of average monthly seizure frequency; (2) doubling of the highest consecutive 2-day seizure total; (3) occurrence of a new, more severe seizure type; or (4) worsening of generalized tonic-clonic seizures.

    Time frame: Study Visit 5 through Visit 9 of the Treatment phase (approximately Week 7 through Week 23)

  4. Percent Change From Baseline in Weekly Seizure Frequency Between Study Visits 3 (Start of Dosing) and 9 (End of the Treatment Phase)

    Change from Baseline was measured as the number of seizures at Visits 3 through 9 minus the number of seizures at Baseline. The number of partial seizures during treatment divided by the number of weeks of treatment was compared to the weekly seizure frequency during Baseline. A positive number equals a reduction in seizure frequency.

    Time frame: Baseline and Study Visit 3 through Visit 9 of the Treatment phase (Treatment Week 0 through Week 23)

  5. Number of Seizure-free Participants During the Last 12 Weeks of Treatment of the Treatment Phase

    The number of participants who had no seizures during the treatment period was calculated. The last 12 weeks of treatment were either Weeks 11-22 or 12-23 depending on which background AED was being withdrawn

    Time frame: The last 12 weeks of treatment of the Treatment phase (Monotherapy phase - approximately Week 11 through Week 23)

  6. Percent Change From Baseline in the Average Seizure Frequency Measured at the End of Participation in the Continuation Phase

    Change from baseline was calculated as the average seizure frequency at the end of the Continuation Phase minus the average seizure frequency at Baseline. The number of seizures during the Continuation phase divided by the number of weeks was compared to the number of seizures at Baseline. A positive number indicates a reduction in seizure frequency.

    Time frame: Baseline and start of Continuation phase through Week 24 or end of participation in the Continuation phase

  7. The Number of Participants With at Least the Specified Change in Seizure Frequency, Compared to Baseline, at the End of Participation in the Continuation Phase (Maximum of 24 Weeks)

    Change in seizure frequency was calculated as the average seizure frequency during the Continuation Phase minus the seizure frequency at Baseline.

    Time frame: Baseline and entire Continuation phase (24 Weeks)

07

Results

Posted Nov 25, 2009

Participant flow

All participants in the Treatment phase and all Baseline Failure participants are eligible to enter the Continuation phase. The Continuation phase is for long-term safety exposure to lamotrigine extended release (LTG XR) at 300 mg/day; it is not a cross-over phase.

Double-Blind (DB) Treatment Phase
Participant flow — Double-Blind (DB) Treatment Phase
MilestoneLamotrigine Extended-release (LTG XR), 300 mgLTG XR, 250 mgBaseline Failures
Started1131130
Completed94790
Not completed19340
Withdrew: Adverse event4100
Withdrew: Withdrawal by subject980
Withdrew: Lack of efficacy670
Withdrew: Lost to follow-up040
Withdrew: Protocol violation040
Withdrew: Pregnancy010
Continuation Phase
Participant flow — Continuation Phase
MilestoneLamotrigine Extended-release (LTG XR), 300 mgLTG XR, 250 mgBaseline Failures
Started184011
Completed16008
Not completed2403
Withdrew: Adverse event201
Withdrew: Lost to follow-up201
Withdrew: Protocol violation101
Withdrew: Withdrawal by subject400
Withdrew: Lack of efficacy500
Withdrew: Site closed by sponsor800
Withdrew: Scheduling error100
Withdrew: Ran out of drug due to travel100

Outcome measures

PrimaryThe Percentage of Participants in the 300 mg/Day Dose Group Who Prematurely Discontinued the Study Between Study Visit 5 (Approximately Week 7) and Visit 9 (End of the Treatment Phase)

The percentage of participants prematurely discontinuing the study was calculated as the number of participants who discontinued the study divided by the number who reached Visit 5 minus major protocol violators. The Control group is composed of data from other similar studies and is not part of this study.

Time frame:
From Study Visit 5 through Visit 9 of the Treatment Phase (approximately Week 7 through Week 23)
Reported as:
Number · percentage of participants
The Percentage of Participants in the 300 mg/Day Dose Group Who Prematurely Discontinued the Study Between Study Visit 5 (Approximately Week 7) and Visit 9 (End of the Treatment Phase)
percentage of participantsLamotrigine Extended-release (LTG XR), 300 mg
The Percentage of Participants in the 300 mg/Day Dose Group Who Prematurely Discontinued the Study Between Study Visit 5 (Approximately Week 7) and Visit 9 (End of the Treatment Phase)12
SecondaryThe Percentage of Participants in the 250 mg/Day Dose Group Who Prematurely Discontinued the Study Between Study Visit 5 (Approximately Week 7) and Visit 9 (End of the Treatment Phase)

The percentage of participants prematurely discontinuing the study was calculated as the number of participants who discontinued the study divided by the number who had reached Visit 5 minus major protocol violators. The Control group was composed of data from other similar studies and is not part of this study.

Time frame:
From Study Visit 5 through Visit 9 of the Treatment phase (approximately Week 7 through Week 23)
Reported as:
Number · percentage of participants
The Percentage of Participants in the 250 mg/Day Dose Group Who Prematurely Discontinued the Study Between Study Visit 5 (Approximately Week 7) and Visit 9 (End of the Treatment Phase)
percentage of participantsLTG XR, 250 mg
The Percentage of Participants in the 250 mg/Day Dose Group Who Prematurely Discontinued the Study Between Study Visit 5 (Approximately Week 7) and Visit 9 (End of the Treatment Phase)16
SecondaryTime to Discontinuation in the Treatment Phase

Time (days) until the participant discontinued the study

Time frame:
From Study Visit 5 through Visit 9 of the Treatment phase (approximately Week 7 through Week 23)
Reported as:
Mean · Days
Time to Discontinuation in the Treatment Phase
DaysLamotrigine Extended-release (LTG XR), 300 mgLTG XR, 250 mg
Time to Discontinuation in the Treatment Phase147.3 ± 31.5133.2 ± 45.6
SecondaryPercentage of Participants Meeting Escape Criteria in the Treatment Phase

The percentage of participants meeting Escape Criteria was calculated as the number of participants who met an Escape Criterion divided by the number who had reached Visit 5 minus major protocol violators. Escape Criteria are: (1) doubling of average monthly seizure frequency; (2) doubling of the highest consecutive 2-day seizure total; (3) occurrence of a new, more severe seizure type; or (4) worsening of generalized tonic-clonic seizures.

Time frame:
Study Visit 5 through Visit 9 of the Treatment phase (approximately Week 7 through Week 23)
Reported as:
Number · percentage of participants
Percentage of Participants Meeting Escape Criteria in the Treatment Phase
percentage of participantsLamotrigine Extended-release (LTG XR), 300 mgLTG XR, 250 mg
Percentage of Participants Meeting Escape Criteria in the Treatment Phase46
SecondaryPercent Change From Baseline in Weekly Seizure Frequency Between Study Visits 3 (Start of Dosing) and 9 (End of the Treatment Phase)

Change from Baseline was measured as the number of seizures at Visits 3 through 9 minus the number of seizures at Baseline. The number of partial seizures during treatment divided by the number of weeks of treatment was compared to the weekly seizure frequency during Baseline. A positive number equals a reduction in seizure frequency.

Time frame:
Baseline and Study Visit 3 through Visit 9 of the Treatment phase (Treatment Week 0 through Week 23)
Reported as:
Median · percent change in seizures
Percent Change From Baseline in Weekly Seizure Frequency Between Study Visits 3 (Start of Dosing) and 9 (End of the Treatment Phase)
percent change in seizuresLamotrigine Extended-release (LTG XR), 300 mgLTG XR, 250 mg
Percent Change From Baseline in Weekly Seizure Frequency Between Study Visits 3 (Start of Dosing) and 9 (End of the Treatment Phase)54.8 (-124.5 to 100.0)52.2 (-221.3 to 100.0)
SecondaryNumber of Seizure-free Participants During the Last 12 Weeks of Treatment of the Treatment Phase

The number of participants who had no seizures during the treatment period was calculated. The last 12 weeks of treatment were either Weeks 11-22 or 12-23 depending on which background AED was being withdrawn

Time frame:
The last 12 weeks of treatment of the Treatment phase (Monotherapy phase - approximately Week 11 through Week 23)
Reported as:
Number · participants
Number of Seizure-free Participants During the Last 12 Weeks of Treatment of the Treatment Phase
participantsLamotrigine Extended-release (LTG XR), 300 mgLTG XR, 250 mg
Number of Seizure-free Participants During the Last 12 Weeks of Treatment of the Treatment Phase228
SecondaryPercent Change From Baseline in the Average Seizure Frequency Measured at the End of Participation in the Continuation Phase

Change from baseline was calculated as the average seizure frequency at the end of the Continuation Phase minus the average seizure frequency at Baseline. The number of seizures during the Continuation phase divided by the number of weeks was compared to the number of seizures at Baseline. A positive number indicates a reduction in seizure frequency.

Time frame:
Baseline and start of Continuation phase through Week 24 or end of participation in the Continuation phase
Reported as:
Median · percent change in seizures
Percent Change From Baseline in the Average Seizure Frequency Measured at the End of Participation in the Continuation Phase
percent change in seizuresLamotrigine Extended-release (LTG XR), 300 mgBaseline Failures
Percent Change From Baseline in the Average Seizure Frequency Measured at the End of Participation in the Continuation Phase72.2 (-840.7 to 100.0)68.8 (-111 to 100)
SecondaryThe Number of Participants With at Least the Specified Change in Seizure Frequency, Compared to Baseline, at the End of Participation in the Continuation Phase (Maximum of 24 Weeks)

Change in seizure frequency was calculated as the average seizure frequency during the Continuation Phase minus the seizure frequency at Baseline.

Time frame:
Baseline and entire Continuation phase (24 Weeks)
Reported as:
Number · participants
The Number of Participants With at Least the Specified Change in Seizure Frequency, Compared to Baseline, at the End of Participation in the Continuation Phase (Maximum of 24 Weeks)
participantsLamotrigine Extended-release (LTG XR), 300 mgBaseline Failures
At least a 25% reduction in seizures1697
At least a 50% reduction in seizures1376
At least a 75% reduction in seizures853
100% reduction in seizures382
At least a 50% increase in seizures63

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Treatment Phase: LTG XR, 300 mg—3/112 (2.7%)44/112 (39.3%)
Treatment Phase: LTG XR, 250 mg—5/111 (4.5%)52/111 (46.8%)
Continuation Phase: LTG XR, 300 mg—3/184 (1.6%)47/184 (25.5%)
Continuation Phase: Baseline Failures—1/11 (9.1%)4/11 (36.4%)
Most frequent serious events
Showing 10 of 14
Most frequent serious events
EventTreatment Phase: LTG XR, 300 mgTreatment Phase: LTG XR, 250 mgContinuation Phase: LTG XR, 300 mgContinuation Phase: Baseline Failures
Status epilepticusNervous system disorders0/1120/1110/1841/11
ConcussionInjury, poisoning and procedural complications0/1121/1110/1840/11
FeverGeneral disorders0/1121/1110/1840/11
Generalized seizureNervous system disorders0/1121/1110/1840/11
Liver CancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1121/1110/1840/11
RashSkin and subcutaneous tissue disorders0/1121/1110/1840/11
Upper GI bleedingGastrointestinal disorders0/1121/1110/1840/11
Brain cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/1120/1110/1840/11
Grand mal seizureNervous system disorders1/1120/1110/1840/11
Head InjuryInjury, poisoning and procedural complications1/1120/1111/1840/11
Most frequent other events
Most frequent other events
EventTreatment Phase: LTG XR, 300 mgTreatment Phase: LTG XR, 250 mgContinuation Phase: LTG XR, 300 mgContinuation Phase: Baseline Failures
HeadacheNervous system disorders29/11231/11133/1841/11
DizzinessNervous system disorders12/11210/11111/1842/11
RashSkin and subcutaneous tissue disorders4/11212/1110/1840/11
Back painMusculoskeletal and connective tissue disorders0/1120/1115/1841/11
NauseaGastrointestinal disorders6/1126/1116/1841/11
SomnolenceNervous system disorders5/1126/1115/1841/11
NasalpharyngitisInfections and infestations7/1127/1115/1840/11
InsomniaPsychiatric disorders0/1125/1110/1840/11

Baseline characteristics

Age, Continuous
Age, Continuous(years)Treatment Phase: LTG XR, 300 mgTreatment Phase: LTG XR, 250 mgTotal
Mean33.8 ± 14.332.9 ± 12.633.4 ± 13.5
Gender
Gender(Participants)Treatment Phase: LTG XR, 300 mgTreatment Phase: LTG XR, 250 mgTotal
Female5666122
Male5645101
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Treatment Phase: LTG XR, 300 mgTreatment Phase: LTG XR, 250 mgTotal
African American549
Asian111122
Arabic/North African022
White9694190
Asian - Central/South Asian000
Asian - East Asian000
Number of participants taking indicated concurrent antiepileptic drug at study entry
Number of participants taking indicated concurrent antiepileptic drug at study entry(participants)Treatment Phase: LTG XR, 300 mgTreatment Phase: LTG XR, 250 mgTotal
Valproate7370143
Levetiracetam111324
Oxcarbazepine121224
Topiramate121022
Zonisamide358
Pregabalin112
08

Study locations

103 sites
  • GSK Investigational Site
    Alabaster, Alabama 35007, United States
  • GSK Investigational Site
    Litchfield Park, Arizona 85340, United States
  • GSK Investigational Site
    Mesa, Arizona 85201, United States
  • GSK Investigational Site
    Phoenix, Arizona 85003, United States
  • GSK Investigational Site
    Phoenix, Arizona 85013, United States
  • GSK Investigational Site
    Tucson, Arizona 85724, United States
  • GSK Investigational Site
    Tucson, Arizona 85741, United States
  • GSK Investigational Site
    Fayetteville, Arkansas 72703, United States
  • GSK Investigational Site
    Los Angeles, California 90073, United States
  • GSK Investigational Site
    Pasadena, California 91105, United States
  • GSK Investigational Site
    Santa Ana, California 92705, United States
  • GSK Investigational Site
    Santa Monica, California 90404, United States
  • GSK Investigational Site
    Danbury, Connecticut 06810, United States
  • GSK Investigational Site
    Fairfield, Connecticut 06824, United States
  • GSK Investigational Site
    Newark, Delaware 19713, United States
  • GSK Investigational Site
    Jacksonville, Florida 32224, United States
  • GSK Investigational Site
    Loxahatchee, Florida 33470, United States
  • GSK Investigational Site
    Sunrise, Florida 33351, United States
  • GSK Investigational Site
    Tampa, Florida 33613, United States
  • GSK Investigational Site
    Atlanta, Georgia 30338, United States
  • GSK Investigational Site
    Atlanta, Georgia 30342, United States
  • GSK Investigational Site
    Decatur, Georgia 30033, United States
  • GSK Investigational Site
    Boise, Idaho 83702, United States
  • GSK Investigational Site
    Chicago, Illinois 60611, United States
  • GSK Investigational Site
    Chicago, Illinois 60637, United States
  • GSK Investigational Site
    Flossmoor, Illinois 60422, United States
  • GSK Investigational Site
    Urbana, Illinois 61801, United States
  • GSK Investigational Site
    Des Moines, Iowa 50309, United States
  • GSK Investigational Site
    Lexington, Kentucky 40513, United States
  • GSK Investigational Site
    Lexington, Kentucky 40536, United States
  • GSK Investigational Site
    Louisville, Kentucky 40202, United States
  • GSK Investigational Site
    New Orleans, Louisiana 70115, United States
  • GSK Investigational Site
    Bethesda, Maryland 20817, United States
  • GSK Investigational Site
    Glen Burnie, Maryland 21061, United States
  • GSK Investigational Site
    Pikesville, Maryland 21208, United States
  • GSK Investigational Site
    Springfield, Massachusetts 01104, United States
  • GSK Investigational Site
    Detroit, Michigan 48202, United States
  • GSK Investigational Site
    Minneapolis, Minnesota 55455, United States
  • GSK Investigational Site
    St. Cloud, Minnesota 56303, United States
  • GSK Investigational Site
    Hattiesburg, Mississippi 39401, United States
  • GSK Investigational Site
    Kansas City, Missouri 64111, United States
  • GSK Investigational Site
    St. Louis, Missouri 63104, United States
  • GSK Investigational Site
    St. Louis, Missouri 63110, United States
  • GSK Investigational Site
    Henderson, Nevada 89014, United States
  • GSK Investigational Site
    Las Vegas, Nevada 81902, United States
  • GSK Investigational Site
    Las Vegas, Nevada 89106, United States
  • GSK Investigational Site
    Edison, New Jersey 08818, United States
  • GSK Investigational Site
    Vorhees, New Jersey 08043, United States
  • GSK Investigational Site
    Lawrence, New York 11559, United States
  • GSK Investigational Site
    Plainview, New York 11803, United States
  • GSK Investigational Site
    Syracuse, New York 13210, United States
  • GSK Investigational Site
    Asheville, North Carolina 28803, United States
  • GSK Investigational Site
    Columbus, Ohio 43210-1296, United States
  • GSK Investigational Site
    Oklahoma City, Oklahoma 73112, United States
  • GSK Investigational Site
    Philadelphia, Pennsylvania 19107, United States
  • GSK Investigational Site
    Sellersville, Pennsylvania 18960, United States
  • GSK Investigational Site
    Dallas, Texas 75230, United States
  • GSK Investigational Site
    Houston, Texas 77025, United States
  • GSK Investigational Site
    San Antonio, Texas 78229, United States
  • GSK Investigational Site
    San Antonio, Texas 78258, United States
  • GSK Investigational Site
    Temple, Texas 76502, United States
  • GSK Investigational Site
    Midvale, Utah 84047, United States
  • GSK Investigational Site
    Renton, Washington 98055, United States
  • GSK Investigational Site
    Charleston, West Virginia 25301, United States
  • GSK Investigational Site
    Morgantown, West Virginia 26506, United States
  • GSK Investigational Site
    Madison, Wisconsin 53715, United States
  • GSK Investigational Site
    Milwaukee, Wisconsin 53215, United States
  • GSK Investigational Site
    Capital Federal, Buenos Aires 1181, Argentina
  • GSK Investigational Site
    Capital Fefderal, Buenos Aires, Argentina
  • GSK Investigational Site
    Ciudad Autonoma de Buenos Aires, Argentina
  • GSK Investigational Site
    Ciudad Autónoma de Buenos Aires, 1425, Argentina
  • GSK Investigational Site
    Providencia / Santiago, Región Metro De Santiago 7500710, Chile
  • GSK Investigational Site
    Santiago, Región Metro De Santiago 7560356, Chile
  • GSK Investigational Site
    Santiago, Región Metro De Santiago, Chile
  • GSK Investigational Site
    San Jose, Costa Rica
  • GSK Investigational Site
    Busan, 614-735, Korea, Republic of
  • GSK Investigational Site
    Daegu, 700-712, Korea, Republic of
  • GSK Investigational Site
    Daejeon, 301-721, Korea, Republic of
  • GSK Investigational Site
    Seoul, 110-744, Korea, Republic of
  • GSK Investigational Site
    Seoul, 120-752, Korea, Republic of
  • GSK Investigational Site
    Seoul, 135-170, Korea, Republic of
  • GSK Investigational Site
    Seoul, 138-736, Korea, Republic of
  • GSK Investigational Site
    San Juan, 00918, Puerto Rico
  • GSK Investigational Site
    San Juan, 00936, Puerto Rico
  • GSK Investigational Site
    Ekaterinburg, 620102, Russian Federation
  • GSK Investigational Site
    Moscow, 105066, Russian Federation
  • GSK Investigational Site
    Moscow, 117049, Russian Federation
  • GSK Investigational Site
    Moscow, 125412, Russian Federation
  • GSK Investigational Site
    Samara, 443095, Russian Federation
  • GSK Investigational Site
    St.-Petersburg, 193019, Russian Federation
  • GSK Investigational Site
    St.-Petersburg, 194291, Russian Federation
  • GSK Investigational Site
    St.Petersburg, 193167, Russian Federation
  • GSK Investigational Site
    Dnepropetrovsk, 49005, Ukraine
  • GSK Investigational Site
    Donetsk, 83037, Ukraine
  • GSK Investigational Site
    Kharkiv, 61068, Ukraine
  • GSK Investigational Site
    Kyiv, 02660, Ukraine
  • GSK Investigational Site
    Kyiv, Ukraine
  • GSK Investigational Site
    Lugansk, 91045, Ukraine
  • GSK Investigational Site
    Lviv, 79021, Ukraine
  • GSK Investigational Site
    Odesa, 65006, Ukraine

Showing the first 100 of 103 sites across 8 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • French JA, Hammer AE, Vuong A, Messenheimer JA. Analysis of three lamotrigine extended-release clinical trials: comparison of pragmatic ITT and LOCF methodologies. Epilepsy Res. 2012 Aug;101(1-2):141-7. doi: 10.1016/j.eplepsyres.2012.03.015. Epub 2012 Apr 10. PubMed 22497754 ↗
  • French JA, Temkin NR, Shneker BF, Hammer AE, Caldwell PT, Messenheimer JA. Lamotrigine XR conversion to monotherapy: first study using a historical control group. Neurotherapeutics. 2012 Jan;9(1):176-84. doi: 10.1007/s13311-011-0088-3. PubMed 22139591 ↗

Individual participant data

Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2006, a primary completion of Nov 2008 and a completion of Nov 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2009, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 19, 2006
First posted
Jul 21, 2006
Start
May 2006
Primary completionActual
Nov 2008
CompletionActual
Nov 2008
Results first posted
Nov 25, 2009
Last update
Jan 2, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 2, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00355082
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Jul 21, 2006
Start date
May 2006
Primary completion
Nov 2008
Completion
Nov 2008
Results posted
Nov 25, 2009
Last update
Jan 2, 2017

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lamotrigine

Start the discussion